Researchers and AI tools are working together to find drug combinations that could slow IPF scarring and keep lungs working better for longer.
FVC = how much air your lungs can push out. Higher % = healthier lungs. A typical IPF patient starts around 50–60%.
This is a computer model result — not a prescription. Always talk to your doctor before changing anything.
This week, scientists are drawing on a large pool of over 4,000 studies and 1,200 clinical trials (studies that test treatments in real people) focused on IPF — the lung disease that causes slow, harmful scarring. Most new papers this week came from broad medical research, but the steady growth of the IPF knowledge base means doctors have more evidence than ever to guide your care.
An AI system tested many drug combinations to see which might protect lung capacity best. The winner kept FVC (a measure of how much air your lungs can hold and push out) at 98.2% — very close to healthy. That is genuinely exciting because most current treatments only slow the decline rather than nearly holding the line. The combination included several experimental medicines, so these are not available yet, but they give researchers a real target to aim for.
One question to ask your lung doctor at your next visit: 'Are there any new combination treatment trials I might qualify for, and how do my recent breathing test results compare to what they were a year ago?'